博雅生物 (300294.SZ) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4

ValuationView details →

P/E (Fwd)

21.0x

EV/EBITDA

24.3x

Market Cap

CNY 7.28B

MomentumView details →

1D Return

−4.94%

YTD Return

−35.97%

RSI (14)

41.2

ValuationView details →

P/E (Fwd)

21.0x

EV/EBITDA

24.3x

Market Cap

CNY 7.28B

RSI (14)

41.2

MomentumView details →

1D Return

−4.94%

YTD Return

−35.97%

ProfitabilityView details →

Gross Margin

48.13%

Net Margin

0.19%

EBITDA Margin

14.59%

ROE (TTM)

0.05%

ROA (TTM)

0.04%

Asset Turnover

0.22x

GrowthView details →

Revenue YoY

+1.21%

EPS YoY

−98.03%

FCF YoY

—

Revenue CAGR 3Y

−9.29%

EPS CAGR 3Y

−36.52%

EBITDA YoY

—

EarningsView details →

EPS (Actual)

CNY 0.04

EPS Surprise

−89.23%

Beats (12Q)

0/12

Next Q EPS Est

CNY 0.05

Avg Surprise (4Q)

−89.23%

Rev Surprise

0.00%

Capital & dividendView details →

Debt/Equity

0.01x

Current Ratio

6.32x

Quick Ratio

5.00x

Div Yield

1.54%

Div Rate

CNY 0.22

Div Growth 1Y

−76.45%

Financials snapshotView financials →

Revenue (TTM)

1.84B

Net Income (TTM)

3.44M

Op. CF (TTM)

−23.95M

Next earningsOct 22, 2026 →

Latest newsMore news →

Boyaa Bio-Pharmaceutical announced its first-half 2026 results: revenue of 644 million yuan, down 36.14% year-on-year; net profit attributable to shareholders of 51.19 million yuan, down 77.28% year-on-year.15d ago

Boyaa Bio's controlled subsidiary Dalateqi Boyaa Plasma Collection Co., Ltd. obtained a plasma collection license from the Health Commission of Inner Mongolia Autonomous Region, valid from July 17, 2026 to July 16, 2028.30d ago

Similar companies

凯盛新材301069.SZ 中原内配002448.SZ 恒星科技002132.SZ 海特高新002023.SZ 爱迪特301580.SZ 新时达002527.SZ Find similar companies →

Latest newsMore news →

Boyaa Bio-Pharmaceutical announced its first-half 2026 results: revenue of 644 million yuan, down 36.14% year-on-year; net profit attributable to shareholders of 51.19 million yuan, down 77.28% year-on-year.15d ago Boyaa Bio's controlled subsidiary Dalateqi Boyaa Plasma Collection Co., Ltd. obtained a plasma collection license from the Health Commission of Inner Mongolia Autonomous Region, valid from July 17, 2026 to July 16, 2028.30d ago